CBD IL-15SA

CBD IL-15SA appears to refer to an engineered interleukin‑15 superagonist (IL‑15SA) fused to a collagen‑binding domain (CBD), designed to enhance local retention in extracellular matrix while providing potent IL‑15 receptor signaling. IL‑15 superagonists such as IL‑15SA (also known as ALT‑803 or Anktiva) are complexes of a mutated IL‑15 (IL‑15N72D) bound to an IL‑15Rα sushi-domain/IgG1 Fc fusion protein, which markedly prolong serum half‑life and increase potency versus native IL‑15 by more efficiently trans‑presenting IL‑15 to cells expressing IL‑2/IL‑15 receptor β/γ chains.[1][3][5] These agents drive expansion and activation of CD8 T cells and NK cells, enhancing interferon‑γ and TNF‑α production, cytotoxicity, and anti‑tumor or antiviral activity without proportionally expanding CD4 T cells.[1][3][4][5] However, no specific preclinical or clinical data could be identified for a construct explicitly named “CBD IL‑15SA”, and its precise sequence, sponsor, indications, and development status are not documented in available sources.